Gimatecan

DB06721InvestigationalSmall molecule

Gimatecan is an orally available 7-t-butoxyiminomethyl-substituted lipophilic camptothecin derivative.

Chemical structure of Gimatecan
Mechanism
Curator reviewed
Formula / weight
C25H25N3O5 · 447.491 g/mol (avg)
Also known as
(4S)-11-[(E)-(tert-butoxyimino)methyl]-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione · (4S)-4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1-H-pyrano[3',4':6,7]-indolizino-[1,2-b]-quinoline-11-carbaldehyde O-(tert-butyl)-(E)-oxime · 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-11-carboxaldehyde, 4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-, 11-[O-(1,1-dimethylethyl)oxime], (4S)-
Code names
CPT 184 · LBQ 707 · ST 1481

Resolves to

Compound
UNII7KKS9R192FCAS292618-32-7ChEMBLCHEMBL113051
Structure
InChIKeyUIVFUQKYVFCEKJ-OPTOVBNMSA-NSMILES[H]\C(=N/OC(C)(C)C)C1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=CC=C12
Targets
P11387TOP1
Transporters
Q9Y6L6SLCO1B1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1TransporterSubstrate / inhibitor direction, not just membership
Listed above
123Drug interactionsStructured to mechanism, not free text
Sign in
11Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Gimatecan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In